USPTO Examiner MOLOYE TITILAYO - Art Unit 1632

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18807211RECOMBINANT ADENO-ASSOCIATED VIRUS WITH MODIFIED AAV CAPSID POLYPEPTIDESAugust 2024August 2025Allow1221NoNo
18371636FORMATION OF ARRAYS OF PLANAR INTESTINAL CRYPTS POSSESSING A STEM/PROLIFERATIVE CELL COMPARTMENT AND DIFFERENTIATED CELL ZONESeptember 2023September 2024Allow1120YesNo
18137578METHOD AND APPARATUS FOR IMPROVED MESENCHYMAL STEM CELL HARVESTINGApril 2023September 2024Allow1720NoNo
18124921NEURAL TISSUE UNIT AND USE OF SUCH A UNIT FOR IMPLANTATION INTO THE NERVOUS SYSTEM OF A MAMMALMarch 2023June 2025Allow2741YesNo
18157834DROPLET TRAPPING STRUCTURE ARRAY, METHOD FOR SPHEROID TRANSFER AND FORMATION OF SPHEROID ARRAY USING THE SAMEJanuary 2023February 2026Abandon3710NoNo
18006163Composition for Pluripotent Cell Undifferentiated State Maintenance Culture, Medium for Pluripotent Cell Undifferentiated State Maintenance Culture, Method for Pluripotent Cell Undifferentiated State Maintenance Culture, and Method for Producing Pluripotent CellsJanuary 2023March 2026Abandon3810NoNo
18093860A COMPOSITION COMPRISING NICOTINAMIDE MONONUCLEOTIDE AND LEUCOMETHYLENE BLUEJanuary 2023January 2025Abandon2431YesNo
18077938METHODS OF TREATING CANCER USING NK CELLSDecember 2022November 2024Allow2330NoNo
17974466AAV-VECTORS FOR USE IN GENE THERAPY OF CHOROIDEREMIAOctober 2022January 2026Abandon3910NoNo
17965257CUSTOM AUTOLOGOUS VACCINE COMPOSITION, AND A METHOD FOR ITS MANUFACTUREOctober 2022March 2025Abandon2960YesNo
17956771ANIMAL MODEL OF BRAIN TUMOR AND MANUFACTURING METHOD OF ANIMAL MODELSeptember 2022March 2026Allow4120YesNo
17890322METHOD OF MAKING A PERSONALIZED BONE GRAFTAugust 2022March 2026Abandon4310NoNo
17872827COMBINATORIAL CANCER IMMUNOTHERAPYJuly 2022July 2024Abandon2420NoNo
17869514METHODS AND COMPOSITIONS FOR REPROGRAMMING CELLSJuly 2022December 2025Allow4010NoNo
17867881COMPOSITIONS AND METHODS FOR REGULATING PRODUCTION OF A FUSION PROTEIN AND RIBONUCLEIC ACIDJuly 2022March 2024Allow2021YesNo
17853208MESENCHYMAL STEM CELL EXPRESSING HEPATOCYTE GROWTH FACTOR, AND USE THEREOFJune 2022January 2026Abandon4210NoNo
17853259MESENCHYMAL STEM CELL EXPRESSING TRAIL AND CD, AND USE THEREOFJune 2022January 2026Abandon4210NoNo
17841917GROWTH MEDIA FOR THREE-DIMENSIONAL CELL CULTUREJune 2022September 2025Allow3911NoNo
17735802CELL IMMORTALIZATION VIA VORTEX ELECTROPORATION GENE DELIVERYMay 2022December 2025Abandon4410NoNo
17661014Generation of Cell-Based Products for Human ConsumptionApril 2022March 2025Allow3451YesNo
17660165METHODS FOR PREPARING A COMESTIBLE MEAT PRODUCTApril 2022November 2022Allow610YesNo
17660170SUBSTRATES FOR PREPARING A COMESTIBLE MEAT PRODUCTApril 2022November 2022Allow610YesNo
17659589BIOPROSTHETIC TISSUE HAVING A REDUCED PROPENSITY FOR IN VIVO CALCIFICATIONApril 2022September 2025Allow4110NoNo
17762316PHYSICAL MANIPULATION OF TISSUE CULTURED TISSUEMarch 2022September 2022Allow610YesNo
17694432Additive Manufacturing of Functional Myocardial TissueMarch 2022February 2026Abandon4701NoNo
17692530Extracellular Matrix-Derived Gels and Related MethodsMarch 2022February 2026Allow4710YesNo
17674196ENGINEERED ADULT-LIKE HUMAN HEART TISSUEFebruary 2022August 2025Allow4210NoNo
17635978ADENO-ASSOCIATED VIRUS VECTOR DELIVERY OF ALPHA-SARCOGLYCAN AND THE TREATMENT OF MUSCULAR DYSTROPHYFebruary 2022June 2024Allow2721YesNo
17590337USE OF INVERTED TERMINAL REPEATS (ITRS) FROM ADENO-ASSOCIATED VIRUS SEROTYPES 8 AND RH.39 IN GENE THERAPY VECTORSFebruary 2022November 2023Allow2110NoNo
17581639METHODS AND COMPOSITIONS FOR DUAL GLYCAN BINDING AAV2.5 VECTORJanuary 2022December 2022Allow1111YesNo
17572297PLANT FAT-BASED SCAFFOLDS FOR THE GROWTH OF CELL-BASED MEATS AND METHODS OF MAKING SUCH PRODUCTSJanuary 2022May 2023Allow1630YesNo
17624434COMPOSITION FOR PROMOTING PROLIFERATION OF STEM CELLS, CONTAINING, AS ACTIVE INGREDIENT, CP1P OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOFJanuary 2022March 2025Abandon3801NoNo
17557409AAV-ABCD1 CONSTRUCTS AND USE FOR TREATMENT OR PREVENTION OF ADRENOLEUKODYSTROPHY (ALD) AND/OR ADRENOMYELONEUROPATHY (AMN)December 2021August 2023Allow2031YesNo
17553115METHODS FOR PRODUCING ANTIGEN-BINDING PROTEINS AGAINST FOREIGN ANTIGENSDecember 2021February 2025Allow3810YesNo
17538206COMPOSITIONS AND METHODS FOR PRODUCING GENETICALLY MODIFIED ANIMALSNovember 2021November 2023Allow2341YesNo
17522988SINGLE CELLS PLURIPOTENT STEM CELLS IN A SUSPENSION CULTURENovember 2021October 2025Allow4820NoNo
17507454USE OF NEUROPILIN-1 (NRP1) AS A CELL SURFACE MARKER FOR ISOLATING HUMAN CARDIAC VENTRICULAR PROGENITOR CELLSOctober 2021June 2025Allow4311NoNo
17497356ORGAN REGENERATION METHOD UTILIZING BLASTOCYST COMPLEMENTATIONOctober 2021October 2025Abandon4811NoNo
17483079GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC GENESSeptember 2021September 2025Abandon4801NoNo
17471776METHODS AND COMPOSITIONS FOR EFFICIENT DELIVERY OF NUCLEIC ACIDS AND RNA-BASED ANTIMICROBIALSSeptember 2021February 2026Allow5311NoNo
17469578CRISPR/CPF1 SYSTEMS AND METHODSSeptember 2021September 2025Allow4820YesNo
17466237ADENO-ASSOCIATED VIRUS VECTORSeptember 2021August 2025Abandon4840YesYes
17464727SCALABLE LENTIVIRAL VECTOR PRODUCTION SYSTEM COMPATIBLE WITH INDUSTRIAL PHARMACEUTICAL APPLICATIONSSeptember 2021November 2024Abandon3901NoNo
17465801Engineered Liver Tissues, Arrays Thereof, and Methods of Making the SameSeptember 2021September 2025Abandon4810NoNo
17445282NUCLEAR REPROGRAMMING FACTOR AND INDUCED PLURIPOTENT STEM CELLSAugust 2021July 2025Allow4720YesNo
17373944Use of neuroglobin agonist for preventing or treating mitochondrial RCCI and/or RCCIII deficiency diseaseJuly 2021August 2024Abandon3710NoNo
17373523Human Pluripotent Stem Cell-Based Models for Predictive Developmental Neural ToxicityJuly 2021January 2026Allow5540NoNo
17367027FUSION PROTEINS COMPRISING PDGF AND VEGF BINDING PORTIONS AND METHODS OF USING THEREOFJuly 2021July 2025Abandon4811YesNo
17304235PLANT FAT-BASED SCAFFOLDS FOR THE GROWTH OF CELL-BASED MEATS AND METHODS OF MAKING SUCH PRODUCTSJune 2021August 2025Allow5030YesNo
17348174METHOD FOR INDUCING DIFFERENTIATION OF CORNEAL EPITHELIAL CELLS FROM PLURIPOTENT STEM CELLSJune 2021November 2024Allow4121YesNo
17344064METHODS FOR GENERATING AND USING ORGANOIDS AND TISSUE THEREINJune 2021July 2024Allow3760YesNo
17340434METHOD AND APPARATUS FOR A TISSUE ENGINEERING SYSTEM UTILIZING STACKED LAYERSJune 2021January 2026Allow5511NoNo
17298367THERAPEUTIC AGENT OF PERIPHERAL BLOOD FLOW DISORDERMay 2021December 2025Allow5540YesNo
17320388COMPOSITIONS AND METHODS FOR TREATING LEBER'S HEREDITARY OPTIC NEUROPATHYMay 2021January 2022Allow810NoNo
17319886METHODS OF PREPARING A POLOXAMER FOR USE IN CELL CULTURE MEDIUMMay 2021October 2023Allow3010NoNo
17293109RECOMBINANT YEAST CELLMay 2021April 2025Abandon4711YesNo
17317295COMPOSITIONS AND METHODS FOR TREATING LEBER'S HEREDITARY OPTIC NEUROPATHYMay 2021September 2024Abandon4040YesYes
17317037NON-DECELLULARIZED PLANT LEAF CULTURES FOR MEATMay 2021July 2025Allow5041YesNo
17315593ISOFORM NELL-1 PEPTIDEMay 2021August 2024Allow3921NoNo
17239059Synergistic Genome-Nonintegrating Reprogramming by Micrornas and Transcription FactorsApril 2021September 2023Allow2910NoNo
17227497METHODS FOR PRODUCING RETINAL TISSUE AND RETINA-RELATED CELLApril 2021December 2025Allow5641YesNo
17219569COMBINATORIAL CANCER IMMUNOTHERAPYMarch 2021March 2022Allow1120YesNo
17191378TARGETING DNA VACCINES TO B CELLS AS PRIMARY ANTIGEN PRESENTING CELLSMarch 2021June 2024Abandon3920NoNo
17178127TREATMENT OF DISEASES INVOLVING DEFICIENCY OF ENPP1 OR ENPP3February 2021September 2022Abandon1920YesYes
17264939MODULATION OF mTORCI ACTIVITY AND AUTOPHAGY VIA CIB2-RHEB INTERACTIONFebruary 2021February 2026Allow6040YesNo
17148324NEOEPITOPE VACCINE COMPOSITIONS AND METHODS OF USE THEREOFJanuary 2021December 2021Abandon1221NoNo
17135916RXR-ALPHA GENE KNOCKOUT CELL LINE WITH STABLE AND LOW RXR-ALPHA PROTEIN EXPRESSION AND PRODUCTION METHOD THEREOFDecember 2020November 2024Abandon4701NoNo
17133326CORNEAL ENDOTHELIAL CELL MARKERDecember 2020April 2024Allow4021YesNo
17131514APPARATUSES AND METHODS FOR PREPARING A COMESTIBLE MEAT PRODUCTDecember 2020March 2022Allow1530YesNo
17129706ADAM6 MICEDecember 2020September 2024Allow4511YesNo
17129708ADAM6 MICEDecember 2020December 2023Allow3511YesNo
17253946METHODS OF GLYCOENGINEERING PROTEOGLYCANS WITH DISTINCT GLYCAN STRUCTURESDecember 2020November 2025Abandon5931NoNo
17114888REPROGRAMMING PROGENITOR COMPOSITIONS AND METHODS OF USE THEREOFDecember 2020January 2024Allow3720NoNo
17110446THREE DIMENSIONAL TISSUE PRINTING DEVICE, THREE DIMENSIONAL TISSUE PRINTING METHOD AND ARTIFICIAL SKINDecember 2020August 2024Abandon4521NoNo
17105156DIRECTED STEM CELL RECRUITMENTNovember 2020June 2023Allow3120NoNo
17056710SYSTEM OF CELL EXPANSION AND METHODS OF USING THE SAMENovember 2020January 2025Abandon5011NoNo
17094327MESSENGER RNA THERAPY FOR THE TREATMENT OF ORNITHINE TRANSCARBAMYLASE DEFICIENCYNovember 2020September 2024Allow4621YesNo
17094350APPARATUS AND METHOD FOR LEVITATIONAL BIOFABRICATION OF ORGAN AND TISSUE ENGINEERED CONSTRUCTS USING TISSUE SPHEROIDS AND MAGNETOACOUSTIC BIFIELDNovember 2020March 2024Abandon4010NoNo
17081766RECOMBINANT ADENO-ASSOCIATED VIRUS-MEDIATED EXPRESSION OF FRACTALKINE FOR TREATMENT OF NEUROINFLAMMATORY AND NEURODEGENERATIVE DISEASESOctober 2020July 2023Abandon3310NoNo
17074481METHODS AND COMPOSITIONS FOR FEEDER-FREE PLURIPOTENT STEM CELL MEDIA CONTAINING HUMAN SERUMOctober 2020June 2023Allow3210NoNo
17071627USES OF KINASE INHIBITORS FOR INDUCING AND MAINTAINING PLURIPOTENCYOctober 2020June 2024Allow4420NoNo
17071507TARGETING THE TUMOR MICROENVIRONMENT USING MANIPULATED NKT CELLSOctober 2020July 2023Abandon3310NoNo
17071511TARGETING THE TUMOR MICROENVIRONMENT USING MANIPULATED NKT CELLSOctober 2020September 2023Abandon3510NoNo
17046264CELL STRUCTURE CONNECTION METHOD AND CONNECTION SUPPORT DEVICEOctober 2020April 2025Allow5421YesNo
17063139METHOD FOR DIFFERENTIATION INDUCTION IN CULTURED STEM CELLSOctober 2020May 2024Allow4320YesNo
17044947POLAND SYNDROME AND METHODS OF TREATMENTOctober 2020September 2025Abandon5921NoNo
17039407BIOLOGICALLY ACTIVE C-TERMINAL ARGININE-CONTAINING PEPTIDESSeptember 2020June 2024Abandon4410NoNo
17039839RNA-Guided Endonuclease Expressing Algal Strain for High Efficiency In Vivo Genome EditingSeptember 2020March 2024Allow4220NoNo
17039784ARTIFICIAL RECOMBINANT CHROMOSOME AND USE THEREOFSeptember 2020June 2025Abandon5780YesNo
17044157FORMATION OF ARRAYS OF PLANAR INTESTINAL CRYPTS POSSESSING A STEM/PROLIFERATIVE CELL COMPARTMENT AND DIFFERENTIATED CELL ZONESeptember 2020March 2026Allow6041YesNo
17042635CARDIOMYOCYTE MATURATION PROMOTERSeptember 2020February 2024Allow4110NoNo
17014113PSORIASIS-INDUCED ANIMAL MODEL AND USE THEREOFSeptember 2020December 2023Abandon3920NoNo
17010054GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC GENESSeptember 2020June 2021Allow1011YesNo
17001319MICROVESICLE AND METHOD FOR PRODUCING THE SAMEAugust 2020May 2023Abandon3310NoNo
16991758METHOD FOR RECONSTRUCTING IMMUNE FUNCTION USING PLURIPOTENT STEM CELLSAugust 2020December 2023Allow4020YesNo
16934503SC-BETA CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAMEJuly 2020April 2021Allow910NoNo
16913741METHOD TO BIOENGINEER DESIGNER RED BLOOD CELLS USING GENE EDITING AND STEM CELL METHODOLOGIESJune 2020December 2024Abandon5431NoNo
16958218SCAFFOLDING MATERIAL FOR STEM CELL CULTURES AND STEM CELL CULTURE METHOD USING SAMEJune 2020April 2025Allow5760YesNo
16908037Skeletal muscle augmentation utilizing muscle-derived progenitor compositions, and treatments thereofJune 2020July 2023Abandon3720NoNo
16860519Functional Targeted Brain EndoskeletonizationApril 2020October 2022Abandon3010NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MOLOYE, TITILAYO.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
7
Examiner Affirmed
5
(71.4%)
Examiner Reversed
2
(28.6%)
Reversal Percentile
44.1%
Lower than average

What This Means

With a 28.6% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
65
Allowed After Appeal Filing
14
(21.5%)
Not Allowed After Appeal Filing
51
(78.5%)
Filing Benefit Percentile
28.5%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 21.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner MOLOYE, TITILAYO - Prosecution Strategy Guide

Executive Summary

Examiner MOLOYE, TITILAYO works in Art Unit 1632 and has examined 530 patent applications in our dataset. With an allowance rate of 60.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 41 months.

Allowance Patterns

Examiner MOLOYE, TITILAYO's allowance rate of 60.9% places them in the 21% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by MOLOYE, TITILAYO receive 2.87 office actions before reaching final disposition. This places the examiner in the 83% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by MOLOYE, TITILAYO is 41 months. This places the examiner in the 20% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +51.8% benefit to allowance rate for applications examined by MOLOYE, TITILAYO. This interview benefit is in the 94% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 18.1% of applications are subsequently allowed. This success rate is in the 17% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 39.2% of cases where such amendments are filed. This entry rate is in the 60% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 88.9% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 67% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 82.5% of appeals filed. This is in the 75% percentile among all examiners. Of these withdrawals, 72.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 82.4% are granted (fully or in part). This grant rate is in the 85% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.4% of allowed cases (in the 58% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.